High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma. We have analysed 67 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n ¼ 61) or primary refractory (n ¼ 6) Hodgkin's lymphoma. The 100-day treatment-related mortality was 3%. With a median follow-up of 67 months (range 3.3-161.0) the probabilities of overall survival (OS) and progression-free survival (PFS) at 5 years were 68 and 64%, respectively. Probabilities for OS and PFS at 5 years for patients with chemosensitive relapse (n ¼ 40) were 81 and 78% versus 50 and 35%, respectively, for patients (n ¼ 27) with chemoresistant relapse (P ¼ 0.012 for OS, P ¼ 0.002 for PFS). In multivariate analysis mixed cellularity classical or lymphocyte-depleted classical histology subtype and haemoglobin level of 10 g/dl or less at the time of ASCT were identified as risk factors for worse OS, whereas stage III or IV disease at diagnosis and disease status at ASCT other than complete or partial remission predicted inferior PFS. LACE followed by ASCT is an effective treatment for the majority of patients with chemosensitive relapsed Hodgkin's lymphoma and a proportion of chemorefractory patients also benefit.
Introduction
Approximately two-thirds of patients with advanced Hodgkin's lymphoma are cured with first-line chemotherapy or chemoradiotherapy. For patients with disease relapse high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) has been considered the preferred approach after two randomized studies showed a significant benefit in progression-free survival (PFS) for patients treated with ASCT compared with those who received non-transplant salvage therapy. 1, 2 However, no difference in overall survival (OS) was demonstrated between the two groups, and thus some uncertainty remains. Several studies in patients with relapsed Hodgkin's lymphoma have reported cumulative probability rates for 5-year OS and PFS after HDC and ASCT of 51-75 and 42-52%, respectively. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Other studies which have focussed on patients with chemorefractory relapse 13 or primary resistant disease 14 have demonstrated lower corresponding figures for outcome.
Preparative chemotherapy regimens before ASCT usually contain a combination of drugs with anti-lymphoma efficacy. Examples include cyclophosphamide, etoposide, melphalan, thiotepa, platinum agents and BCNU (carmustine) which have been used widely in schedules such as BEAM (BCNU, etoposide, cytarabine and melphalan), 15 CBV (cyclophosphamide, BCNU and etoposide (VP16-213)), 3, 4 CBVP (CBV plus cisplatin), 6 melphalan with etoposide, 7 and thiotepa with mitoxantrone and carboplatin. 8 Regimens combining total body irradiation with cyclophosphamide or etoposide have not demonstrated improved outcomes. 9 The reported 100-day treatmentrelated mortality after ASCT has been 3-5%. [3] [4] [5] [6] [7] [8] The International Prognostic Factor Project score including age, gender and disease features at diagnosis (disease stage, anaemia, albumin level, lymphocytopenia and leucocytosis) was developed for patients with newly diagnosed Hodgkin's lymphoma to predict event-free survival (EFS) and OS after initial chemotherapy. 16 This score was subsequently re-evaluated for patients who underwent ASCT for relapsed Hodgkin's lymphoma.
Increased age, low serum albumin, anaemia and lymphocytopenia were associated with inferior EFS and OS after ASCT. 17 Other studies suggested time from diagnosis to relapse, disease stage at relapse and anaemia at relapse were independent prognostic risk factors for inferior PFS after ASCT. 18, 19 Additionally bulky disease, extranodal site of the disease, B symptoms, elevated lactate dehydrogenase (LDH), greater number of chemotherapy regimens before ASCT and less than partial remission (PR) at the time of ASCT were shown to have a negative impact on outcome in other smaller studies. [5] [6] [7] [8] [9] [10] [11] Late treatment complications of HDC and ASCT, including loss of fertility, premature menopause, cardiopulmonary toxicity and increased risk of secondary malignancy, are an important issue for patients with relapsed Hodgkin's lymphoma considering the median age at initial diagnosis of approximately 35 years. Studies have suggested that the incidence of secondary malignancy following HDC and ASCT is higher in patients with Hodgkin's lymphoma than with non-Hodgkin's lymphoma (6-8 versus 3%) and that the number of relapses before ASCT and previous radiotherapy are associated with an increased risk. 20, 21 We have analysed and report here the outcomes of ASCT after a preparative chemotherapy regimen consisting of lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide and etoposide (LACE) in 67 patients with relapsed or primary refractory Hodgkin's lymphoma transplanted at this centre between 1991 and 2004.
Patients and methods

Patients
All patients with relapsed or primary refractory Hodgkin's lymphoma treated with ASCT at this centre between 1991 and 2004 have been included in this analysis. After the diagnosis of relapse or refractory disease patients were evaluated for eligibility to undergo autologous stem cell harvest and HDC. Patients were considered eligible if they met the following inclusion criteria: age between 16 and 70 years, performance status 0-2 (WHO (World Health Organization)), left ventricular ejection fraction greater than 40%, creatinine clearance greater than 40 ml/min and adequate lung function on formal testing.
Treatment plan
From 1991 to 1995 bone marrow harvest was performed for stem cell collection but from 1996 onwards peripheral blood stem cells were mobilized with intravenous etoposide (1.6 g/m 2 ) and granulocyte-colony stimulating factor (G-CSF, Lenograstim, Chugai Pharma, London, UK) at a dose of 5 mg/kg daily. In cases of failed peripheral blood stem cell mobilization bone marrow harvest was performed. The LACE chemotherapy regimen consisted of oral lomustine (CCNU) 200 mg/m 2 on day À7, intravenous etoposide 1000 mg/m 2 infused over 10 h on day À7, intravenous cytarabine (Ara-C) 2000 mg/m 2 infused over 12 h on days À6 and À5 and intravenous cyclophosphamide 1800 mg/m 2 infused over 1 h on days À4, À3
and À2. Patients also received intravenous MESNA 1800 mg/m 2 twice daily over 12 h on days À4, À3 and À2. Autologous stem cells were infused on day 0, 48 h after the end of the last cyclophosphamide infusion. Patients received standard supportive treatment including transfusion support and intravenous antibiotic treatment for neutropenic sepsis.
Outcome evaluation and statistical analysis Standard remission criteria were applied to assess disease response to first-line chemotherapy, disease status following salvage chemotherapy but before HDC with ASCT, and response at 3 months after ASCT. Patients were assessed for treatment toxicity in the first 100 days after ASCT and for disease status at 3, 6 and 12 months and annually thereafter. OS was calculated on the basis that death from any cause was considered an event, and all remaining patients were censored at the last visit date. In estimating PFS, relapse, disease progression or death were considered events, whereas patients with stable disease (SD) or in remission were censored. Probabilities of OS and PFS were estimated using the Kaplan-Meier method. Univariate comparisons of survival times for potential prognostic factors were made using the log-rank test. Variables with P-values o0.20 were then entered into a proportional hazards regression analysis and a forward stepping procedure utilized to identify independent factors associated with either OS or PFS. All P-values are from twosided tests, and those o0.05 were deemed statistically significant.
Results
Patient characteristics and treatment before LACE and ASCT Sixty-seven patients (21 female, 46 male) were treated with LACE and ASCT for relapsed (n ¼ 61) or primary refractory (n ¼ 6) Hodgkin's lymphoma between 1991 and 2004. The patient, disease and treatment details are presented in Table 1 . The histological subtype was nodular lymphocyte predominant Hodgkin's lymphoma in three patients (4%), nodular sclerosis classical in 44 (66%), mixed cellularity classical in 10 (15%) and lymphocyte depleted classical in two (3%). The histology subtype was unknown in eight patients (12%).
After first-line therapy 54 patients (80%) had achieved complete or PR, whereas seven patients (11%) had minimal response (MR) and six patients (9%) progressive disease (PD). Following further therapy 61 patients achieved complete remission (CR) and six patients were designated primary refractory disease. Following relapse (or in primary resistant patients) the majority received salvage chemotherapy with dexamethasone, cytarabine, cisplatin or etoposide, methylprednisolone, cytarabine, cisplatin as a single regimen (32 patients, 48%) or in addition to another salvage regimen (10 patients, 15%). Twenty-two patients were treated with other salvage regimens. Three patients received LACE and ASCT without preceding salvage therapy. HDC and ASCT were undertaken in 43 patients (64%) after first disease relapse, in 18 (27%) after second or subsequent relapse, whereas six patients (9%) had primary refractory disease. Following salvage therapy seven patients (10%) had achieved CR, 33 patients (49%) a PR, six patients (9%) had shown MR, one patient SD and 20 patients (30%) PD.
Stem cell mobilization and HDC with ASCT Peripheral blood stem cells were mobilized with etoposide and G-CSF in 56 patients, whereas bone marrow harvest was performed in the other 11 patients. All patients completed LACE chemotherapy according to schedule. The median number of infused peripheral blood stem cells was 4.03 Â 10 6 CD34 þ per kg body weight (range 1.31-18.41 Â 10 6 CD34 þ per kg body weight). In the 11 patients in whom bone marrow stem cells were infused the median number of total nucleated cells was 1.93 Â 10 8 per kg body weight (range 0.77-3.05 Â 10 8 per kg body weight). Following HDC mucositis grade III-IV occurred in five patients (8%). Non-haematological grade III-IV (liver, kidney or cardiac) toxicities occurred in six patients (9%). All patients had successful blood count recovery and reached a neutrophil count 40.5 Â 10 9 /l at a median of 14 days (range 10-33 days) and platelet count 450 Â 10 9 /l at a median of 18 days (range 10-43) following stem cell reinfusion.
Treatment toxicity
Significant toxicity following the LACE chemotherapy regimen was uncommon. Mucositis of grade III-IV occurred in five patients (8%). Grade III-IV non-haematological (liver, kidney or cardiac) toxicities occurred in six patients (9%). Two patients (3%) died of infection on day 43 and 45 from ASCT despite achieving blood count recovery. Non-infectious deaths were not observed in the first 100 days following LACE and ASCT.
Treatment response and survival analysis OS. With a median follow-up of 67 months (range 3.3-161.0) the probability of OS was 68% at 5 years and 60% at 10 years (Figure 1) . In univariate analysis gender, age at diagnosis (or age at ASCT), B symptoms at diagnosis, disease stage at presentation, extranodal disease, bulk disease or bone marrow involvement at diagnosis, initial treatment type, response to first-line chemotherapy, duration of first remission, number of treatment lines before ASCT, LDH at ASCT and albumin at ASCT did not have an impact on OS (data not shown). However, associated with a survival advantage were: nodular lymphocyte predominant or nodular sclerosis classical histology subtype (versus other subtypes, P ¼ 0.001), and a haemoglobin level at ASCT of 410 g/dl (P ¼ 0.028) ( Table 2) . Compared with patients with MR, SD or PD at the time of ASCT there was also a better OS at 5 years for patients with CR or PR at the time of ASCT (81% versus 50%, P ¼ 0.012) (Figure 2) . In multivariate analysis, however, mixed cellularity classical or lymphocyte depleted classical histology relative risk ((RR): 5.27 (1.8-15.5), P ¼ 0.002) and haemoglobin less than or equal to 10 g/dl (RR: 5.57 (1.5-20.7), P ¼ 0.01) were identified as the only independent risk factors for worse OS (Table 3) . Patients with primary refractory disease (n ¼ 6) had a 5-year probability of OS of 67% (data not shown).
PFS. The probability of PFS was 64% at 5 years and 51% at 10 years. CR or PR before ASCT had a 5-year PFS probability of 78.2 versus 35.2% for other patients. However, in multivariate analysis stages at diagnosis (P ¼ 0.011) and disease status at ASCT (P ¼ 0.003) were identified as the only independent prognostic factors for PFS (Table 3) . Patients with primary refractory disease (n ¼ 6) had a 5-year probability of PFS of 50% (data not shown).
Late effects and secondary malignancy Two patients developed acute myeloid leukaemia 4 and 9 years, respectively, after ASCT. Two other patients developed solid tumours: squamous cell carcinoma of the oesophagus and adenocarcinoma of the lung 7 and 12 years, respectively, after ASCT. Thus, assuming these events were secondary to previous therapy, the cumulative 5-and 10-year probabilities of developing a secondary malignancy were 3.8 and 17%, respectively. Detailed analysis of gonadal function and fertility recovery have not been carried out. One female patient who was 29 years old at the time of ASCT conceived a child naturally 18 months after ASCT, and three male patients who underwent ASCT aged 20, 22 and 28 years fathered children naturally 3-5 years after ASCT.
Discussion
HDC with ASCT is a recognized treatment for patients with relapsed Hodgkin's lymphoma. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [22] [23] [24] [25] Several regimens have been used as preparative chemotherapy before ASCT [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] but few comparative studies exist 1,2 and none of the regimens has been demonstrated superior. We analyse here the survival data of 67 patients with relapsed or primary refractory Hodgkin's lymphoma treated with LACE. This regimen was generally well tolerated with a low incidence of non-haematological grade III-IV toxicity.
The 100-day mortality of 3% was comparable with other studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The 5-year probabilities of OS and PFS of 68 and 64%, respectively, also compare well with data reported elsewhere. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] We conclude that LACE chemotherapy is a well tolerated and effective preparative chemotherapy regimen before ASCT in patients with relapsed or primary refractory Hodgkin's lymphoma.
Analyses of prognostic factors in patients with relapsed or primary refractory Hodgkin's lymphoma have been described by several groups. In this present study, multivariate analysis identified two histological subtypes (nodular lymphocyte predominant and nodular sclerosis classical) and absence of anaemia at ASCT as favourable prognostic factors for OS, whereas limited disease (stages I and II) at diagnosis and CR or PR disease status at the time of ASCT were favourable prognostic factors for PFS.
Several studies have demonstrated a worse outcome for patients receiving ASCT with chemorefractory as compared with chemosensitive relapse. [13] [14] [15] 18 The data from the study reported here suggests that ASCT is indeed beneficial in a significant proportion of patients with chemorefractory relapse as the 5-year probabilities of OS and PFS were 50 and 35%, respectively.
Josting et al. 19 reported a cohort of 471 patients with relapsed Hodgkin's lymphoma in whom multivariate analysis identified time to relapse, disease stage and anaemia at relapse as prognostic factors for better PFS. In this present study of 67 patients anaemia at ASCT and disease stage were found to be prognostic factors for OS and PFS, respectively, but time to relapse had no significant influence. The data from this study suggest that patients with relapsed Hodgkin's lymphoma and characteristics such as unfavourable histological subtype, anaemia at ASCT, advanced disease stage at diagnosis or poor disease control (MR, SD or PD) at ASCT represent a high-risk group for inferior OS or PFS and new therapeutic strategies are needed to improve their outcome. Possible approaches In eight patients the histology subtype was unknown and in five patients the pre-ASCT haemoglobin data were missing; these patients were excluded from analysis.
for such patients may include tandem or high-dose sequential chemotherapy, 10, 22, 23 allogeneic stem cell transplantation, 24 radiolabelled antibodies, 25 the proteasome inhibitor bortezomib, 26 and immunotherapy such as rituximab. 27 Late treatment complications of HDC and ASCT are particularly relevant for Hodgkin's lymphoma patients because of the low median age at diagnosis. The 3.8 and 17% cumulative rates of secondary malignancy at 5 and 10 years in this cohort are similar to previously reported data. 21, [28] [29] [30] A recent report of the Vancouver long-term outcome data in Hodgkin's lymphoma patients after ASCT found a cumulative risk of secondary malignancy of 9% at 15 years. 29 Another study found a cumulative risk of 16.7% after 13 years following ASCT for malignant lymphomas. 30 The number of patients in this present study is relatively small and the median follow-up relatively short but the results appear comparable with reported data. A detailed study of post-ASCT fertility recovery has not been carried out in this patient group, but clearly patients are potentially fertile following HDC with LACE.
We conclude that LACE and ASCT is an effective salvage treatment with low non-haematological toxicity in patients with relapsed and primary refractory Hodgkin's lymphoma. The data from this study indicate that this approach may be recommended for eligible patients independent of initial treatment response, response duration or number of relapses. However, innovative therapies may be needed to improve OS and PFS in patients with relapsed Hodgkin's lymphoma and high-risk criteria such as unfavourable histology, advanced stage at diagnosis, and anaemia or poor disease control at ASCT.
